Introduction Because the treatment landscape for metastatic renal cell carcinoma (mRCC)
has evolved dramatically over the past decade, data on patients' treatment and outcomes in …

Background Only a few recent phase III trials with targeted therapies or immune checkpoint
inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an …

Purpose To describe factors associated with overall survival (OS) among patients with
metastatic clear-cell renal-cell carcinoma (mccRCC) in regard to evolution of systemic …

CONTEXT: The expanding armamentarium of agents for the therapy of advanced clear cell
renal cell carcinoma (RCC) warrants further investigation of optimal patient selection …

Background The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC)
has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more …

Introduction The aim of this retrospective clinical study was to assess, in the context of the
recent evolution of systemic therapies, the potential effect of targeted therapies on overall …

Background Clinical data from patients with non–clear cell renal cell carcinoma (nccRCC)
receiving targeted therapy are limited, and many clinical trials have excluded these patients …

Renal cell carcinoma (RCC) accounts for 2.4% of all malignancies worldwide diagnosed
with 338,000 estimated new cases globally in 2012. In the last decade, the therapeutic …

Opinion statement Treatment of metastatic clear cell renal cancer (mccRCC) has seen
substantial progress over the last 20 years, with many regulatory approvals since 2006 …

Background Second-line systemic treatment options for metastatic clear cell renal cell
cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim …